J. Kuhlmann

1.8k total citations
94 papers, 1.2k citations indexed

About

J. Kuhlmann is a scholar working on Pediatrics, Perinatology and Child Health, Pharmacology and Molecular Biology. According to data from OpenAlex, J. Kuhlmann has authored 94 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Pediatrics, Perinatology and Child Health, 21 papers in Pharmacology and 18 papers in Molecular Biology. Recurrent topics in J. Kuhlmann's work include Analytical Methods in Pharmaceuticals (18 papers), Pharmacogenetics and Drug Metabolism (14 papers) and Pharmaceutical studies and practices (13 papers). J. Kuhlmann is often cited by papers focused on Analytical Methods in Pharmaceuticals (18 papers), Pharmacogenetics and Drug Metabolism (14 papers) and Pharmaceutical studies and practices (13 papers). J. Kuhlmann collaborates with scholars based in Germany, United States and Sweden. J. Kuhlmann's co-authors include Wolfgang Mück, N. Rietbrock, Georg Wensing, S. Unger, Gunnar Alván, Svein G. Dahl, Gilles Paintaud, Meindert Danhof, G. Ahr and W. Ritter and has published in prestigious journals such as Advanced Energy Materials, Biological Psychiatry and Antimicrobial Agents and Chemotherapy.

In The Last Decade

J. Kuhlmann

86 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
J. Kuhlmann Germany 20 246 212 174 171 162 94 1.2k
Achiel Van Peer Belgium 19 319 1.3× 208 1.0× 129 0.7× 215 1.3× 202 1.2× 43 1.2k
Peter H. Hinderling United States 19 200 0.8× 252 1.2× 70 0.4× 186 1.1× 131 0.8× 48 1.1k
Julie Ducharme Canada 20 341 1.4× 323 1.5× 105 0.6× 221 1.3× 153 0.9× 45 1.3k
Robert Z. Harris United States 19 401 1.6× 313 1.5× 114 0.7× 163 1.0× 200 1.2× 28 1.6k
Robert A. Ronfeld United States 18 260 1.1× 147 0.7× 139 0.8× 236 1.4× 148 0.9× 29 1.0k
Douglas C. Throckmorton United States 17 310 1.3× 490 2.3× 129 0.7× 170 1.0× 169 1.0× 28 1.7k
Eric Pussard France 23 138 0.6× 285 1.3× 260 1.5× 118 0.7× 176 1.1× 96 1.6k
Douglas S. Greene United States 20 268 1.1× 236 1.1× 127 0.7× 487 2.8× 154 1.0× 66 1.4k
Theodor W. Guentert Switzerland 19 394 1.6× 264 1.2× 52 0.3× 244 1.4× 174 1.1× 40 1.1k
Philippe Coassolo Switzerland 20 577 2.3× 271 1.3× 124 0.7× 81 0.5× 83 0.5× 45 1.4k

Countries citing papers authored by J. Kuhlmann

Since Specialization
Citations

This map shows the geographic impact of J. Kuhlmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Kuhlmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Kuhlmann more than expected).

Fields of papers citing papers by J. Kuhlmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Kuhlmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Kuhlmann. The network helps show where J. Kuhlmann may publish in the future.

Co-authorship network of co-authors of J. Kuhlmann

This figure shows the co-authorship network connecting the top 25 collaborators of J. Kuhlmann. A scholar is included among the top collaborators of J. Kuhlmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Kuhlmann. J. Kuhlmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Kuhlmann, J. & Georg Wensing. (2006). The Applications of Biomarkers in Early Clinical Drug Development to Improve Decision-Making Processes. Current Clinical Pharmacology. 1(2). 185–191. 25 indexed citations
3.
Kuhlmann, J., et al.. (2005). Adverse events in volunteers participating in phase I clinical trials: a single-center five-year survey in 1,559 subjects. International Journal of Clinical Pharmacology and Therapeutics. 43(5). 217–226. 32 indexed citations
4.
Haase, Claus G., Michael Becka, J. Kuhlmann, & Georg Wensing. (2005). Influences of caffeine, acetazolamide and cognitive stimulation on cerebral blood flow velocities. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 29(4). 549–556. 6 indexed citations
5.
Böettcher, Michael, Roland Heinig, Georg Wensing, & J. Kuhlmann. (2005). Pupil Reaction: A Valid Sensitive Clinical Biomarker for 5‐HT1A Compounds. Basic & Clinical Pharmacology & Toxicology. 96(3). 246–246. 2 indexed citations
6.
Kuhlmann, J., et al.. (2001). Clinical-Pharmacological Strategies to Assess Drug Interaction Potential During Drug Development. Drug Safety. 24(10). 715–725. 60 indexed citations
7.
Voith, Barbara, et al.. (2000). Safety, tolerability, and pharmacokinetics following multiple oral doses of faropenem daloxate and impact on fecal and oral flora. 40. 15. 3 indexed citations
8.
Voith, Barbara, et al.. (2000). Guidances related to bioavailability and bioequivalence: European industry perspective. European Journal of Drug Metabolism and Pharmacokinetics. 25(1). 25–27. 10 indexed citations
9.
Kuhlmann, J.. (1999). Aufgaben der klinischen Pharmakologie in der frühen Phase der Arzneimittelentwicklung. Medizinische Klinik. 94(5). 290–299. 5 indexed citations
10.
Kuhlmann, J., et al.. (1999). The Influence of Valerian Treatment on 'Reaction Time, Alertness and Concentration' in Volunteers. Pharmacopsychiatry. 32(6). 235–241. 51 indexed citations
11.
Gleiter, Christoph H., et al.. (1998). When Are Bioavailability Studies Required? A German Proposal. The Journal of Clinical Pharmacology. 38(10). 904–911. 24 indexed citations
12.
Schaefer, Hans, et al.. (1997). Pharmacokinetic-pharmacodynamic modelling as a tool to evaluate the clinical relevance of a drug-food interaction for a nisoldipine controlled-release dosage form. European Journal of Clinical Pharmacology. 51(6). 473–480. 17 indexed citations
13.
Wensing, Georg, Roland Heinig, & J. Kuhlmann. (1996). Pharmacodynamics and pharmacokinetics of BAY x 7195 aerosol, a new and selective receptor antagonist of cysteinyl‐leukotrienes, in normal volunteers. British Journal of Clinical Pharmacology. 42(2). 171–178. 3 indexed citations
14.
Mück, Wolfgang, et al.. (1995). Nimodipine. Drugs & Aging. 6(3). 229–242. 22 indexed citations
15.
Wensing, Georg, et al.. (1994). Effect of BAY x7195, an oral receptor antagonist of cysteinyl-leukotrienes, on leukotriene D4-induced bronchoconstriction in normal volunteers. European Journal of Clinical Pharmacology. 47(3). 227–230. 2 indexed citations
16.
Schaefer, Hans, et al.. (1993). Effect of food on the pharmacokinetics of the active metabolite of the prodrug repirinast. Journal of Pharmaceutical Sciences. 82(1). 107–109. 4 indexed citations
17.
Beermann, D., et al.. (1992). Pharmacokinetics of the active metabolite of the prodrug repirinast in healthy Caucasian volunteers after a single oral dose. European Journal of Clinical Pharmacology. 42(3). 307–12. 4 indexed citations
18.
Beneke, Manfred, et al.. (1992). Neuroendocrine effects of ipsapirone on the hypothalamic-pituitary adrenal axis: CRF, ACTH and cortisol in healthy volunteers. European Journal of Clinical Pharmacology. 42(2). 163–169. 6 indexed citations
19.
Demol, P., et al.. (1989). Effect of Rioprostil, an Oral Prostaglandin ExAnalogue, on Lower Oesophageal Sphincter Pressure and on the Motility of the Distal Oesophagus in Healthy Volunteers. Scandinavian Journal of Gastroenterology. 24(sup164). 120–126. 3 indexed citations
20.
Ziegler, Ralph, R. Horstmann, W. Wingender, & J. Kuhlmann. (1987). Do dihydropyridines influence pharmacokinetic and hemodynamic parameters of digoxin. The Journal of Clinical Pharmacology. 27(9). 712. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Achiel Van Peer Breakdown of academic impact, for papers by Peter H. Hinderling Breakdown of academic impact, for papers by Julie Ducharme Breakdown of academic impact, for papers by Robert Z. Harris Breakdown of academic impact, for papers by Robert A. Ronfeld Breakdown of academic impact, for papers by Douglas C. Throckmorton Breakdown of academic impact, for papers by Eric Pussard Breakdown of academic impact, for papers by Douglas S. Greene Breakdown of academic impact, for papers by Theodor W. Guentert Breakdown of academic impact, for papers by Philippe Coassolo
Rankless by CCL
2026